» Articles » PMID: 27254664

NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies

Abstract

Nicotinamide mononucleotide adenylyl transferase 2 (NMNAT2) is neuroprotective in numerous preclinical models of neurodegeneration. Here, we show that brain nmnat2 mRNA levels correlate positively with global cognitive function and negatively with AD pathology. In AD brains, NMNAT2 mRNA and protein levels are reduced. NMNAT2 shifts its solubility and colocalizes with aggregated Tau in AD brains, similar to chaperones, which aid in the clearance or refolding of misfolded proteins. Investigating the mechanism of this observation, we discover a novel chaperone function of NMNAT2, independent from its enzymatic activity. NMNAT2 complexes with heat shock protein 90 (HSP90) to refold aggregated protein substrates. NMNAT2's refoldase activity requires a unique C-terminal ATP site, activated in the presence of HSP90. Furthermore, deleting NMNAT2 function increases the vulnerability of cortical neurons to proteotoxic stress and excitotoxicity. Interestingly, NMNAT2 acts as a chaperone to reduce proteotoxic stress, while its enzymatic activity protects neurons from excitotoxicity. Taken together, our data indicate that NMNAT2 exerts its chaperone or enzymatic function in a context-dependent manner to maintain neuronal health.

Citing Articles

Programmed neurite degeneration in human central nervous system neurons driven by changes in NAD metabolism.

Brull M, Multrus S, Schafer M, Celardo I, Karreman C, Leist M Cell Death Dis. 2025; 16(1):24.

PMID: 39824831 PMC: 11742042. DOI: 10.1038/s41419-024-07326-w.


Chronically Low NMNAT2 Expression Causes Sub-lethal SARM1 Activation and Altered Response to Nicotinamide Riboside in Axons.

Antoniou C, Loreto A, Gilley J, Merlini E, Orsomando G, Coleman M Mol Neurobiol. 2024; 62(3):3903-3917.

PMID: 39352636 PMC: 11790816. DOI: 10.1007/s12035-024-04480-2.


NMNAT2 is a druggable target to drive neuronal NAD production.

Tribble J, Joe M, Varricchio C, Otmani A, Canovai A, Habchi B Nat Commun. 2024; 15(1):6256.

PMID: 39048544 PMC: 11269627. DOI: 10.1038/s41467-024-50354-5.


Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability and Clinical Implications.

Benjamin C, Crews R Metabolites. 2024; 14(6).

PMID: 38921475 PMC: 11205942. DOI: 10.3390/metabo14060341.


Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.

Velma G, Krider I, Alves E, Courey J, Laham M, Thatcher G J Med Chem. 2024; 67(8):5999-6026.

PMID: 38580317 PMC: 11056997. DOI: 10.1021/acs.jmedchem.3c02112.


References
1.
Ellis J . Proteins as molecular chaperones. Nature. 1987; 328(6129):378-9. DOI: 10.1038/328378a0. View

2.
Hanger D, Brion J, Gallo J, Cairns N, Luthert P, Anderton B . Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. Biochem J. 1991; 275 ( Pt 1):99-104. PMC: 1150018. DOI: 10.1042/bj2750099. View

3.
Sharma M, Burre J, Sudhof T . CSPα promotes SNARE-complex assembly by chaperoning SNAP-25 during synaptic activity. Nat Cell Biol. 2010; 13(1):30-9. DOI: 10.1038/ncb2131. View

4.
Cummings C, Mancini M, Antalffy B, DeFranco D, Orr H, Zoghbi H . Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet. 1998; 19(2):148-54. DOI: 10.1038/502. View

5.
Soto C, Estrada L . Protein misfolding and neurodegeneration. Arch Neurol. 2008; 65(2):184-9. DOI: 10.1001/archneurol.2007.56. View